Patents by Inventor Steven C. Quay

Steven C. Quay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NASAL CALCITONIN FORMULATIONS CONTAINING CHLOROBUTANOL
    Publication number: 20110009321
    Abstract: An aqueous solution of calcitonin suitable for intranasal administration comprised of calcitonin, chlorobutanol at a concentration of less than 0.4% weight/weight, and water and having a pH of less than 4 with the proviso that benzalkonium chloride is not present in the solution. The aqueous solution of calcitonin can be used to treat osteoporosis, Paget's bone disease and hypercalcemia.
    Type: Application
    Filed: September 9, 2010
    Publication date: January 13, 2011
    Inventors: Steven C. Quay, Jorge C. de Meireles, Arati A. Deshpande, Zenaida O. Go, Anthony P. Sileno
  • Compositions for enhanced epithelial permeation of neuropeptide Y for treating obesity
    Patent number: 7863245
    Abstract: Pharmaceutical compositions comprising PYY(3-36) or Neuropeptide Y (NPY), a cyclodextrin, and a compound selected from phosphatidylcholine or diglyceride, wherein the PYY(3-36) or Neuropeptide Y (NPY) is present in an amount effective to alleviate one or more symptom(s) of obesity in a subject, and the cyclodextrin and the compound selected from phosphatidylcholine or diglyceride are present in an amount sufficient to enhance epithelial permeation.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: January 4, 2011
    Assignee: Nastech Pharmaceutical Company, Inc.
    Inventor: Steven C. Quay
  • Nasal calcitonin formulations containing chlorobutanol
    Patent number: 7812120
    Abstract: Compositions suitable for intranasal administration containing calcitonin, chlorobutanol, a pH of about 3.5, and sodium chloride, and an intranasal spray and a pharmaceutical delivery device thereof.
    Type: Grant
    Filed: March 22, 2004
    Date of Patent: October 12, 2010
    Assignee: Par Pharmaceutical, Inc.
    Inventors: Steven C. Quay, Jorge C. de Meireles, Arati A. Deshpande, Zenaida O. Go, Anthony P. Sileno
  • TIGHT JUNCTION MODULATOR PEPTIDES FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS
    Publication number: 20100247482
    Abstract: Compositions and methods are provided that include a biologically active agent and a permeabilizing agent effective to enhance mucosal delivery of the biologically active agent in a mammalian subject, in which the permeabilizing peptide is a PN159 analog or conjugate.
    Type: Application
    Filed: April 23, 2008
    Publication date: September 30, 2010
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventors: Kunyuan Cui, Shu-Chih Chen, Michael E. Houston, JR., Steven C. Quay
  • INTRANASAL ADMINISTRATION OF RAPID ACTING INSULIN
    Publication number: 20100210506
    Abstract: What is described are pharmaceutical compositions, formulations, and uses thereof, for medicaments for intranasal delivery of insulin to a patient, comprising an aqueous mixture of human insulin, a solubilizing agent, and a surface active agent, wherein the human insulin may be rapid actin insulin.
    Type: Application
    Filed: October 20, 2006
    Publication date: August 19, 2010
    Applicant: MDRNA, INC.
    Inventors: Steven C. Quay, Annemarie Stoudt Cohen, Henry R. Costantino, Shu-Chih Chen Quay, Anthony P. Sileno, Mary S. Kleppe
  • NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF
    Publication number: 20100209487
    Abstract: The present disclosure provides meroduplex (nicked or gapped) ribonucleic acid molecules (mdRNA) that decreases or silences target gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a target gene RNA. In addition, the meroduplex may have one or more modifications or substitutions, such as nucleotide base, sugar, terminal cap structure, internucleotide linkage, or any combination of such modifications. Also provided are methods of decreasing expression of a target gene in a cell or in a subject to treat a disease related to altered expression of a target gene.
    Type: Application
    Filed: October 18, 2007
    Publication date: August 19, 2010
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventors: Steven C. Quay, James Mcswiggen, Narendra K. Vaish, Mohammad Ahmadian
  • COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PARATHYROID HORMONE
    Publication number: 20100184688
    Abstract: Pharmaceutical compositions and methods are described comprising at least a parathyroid hormone peptide (PTH) preferably PTH1-34 and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of PTH, for treating or preventing osteoporosis or osteopenia in a mammalian subject, preferably a human.
    Type: Application
    Filed: March 17, 2010
    Publication date: July 22, 2010
    Applicant: MDRNA, INC.
    Inventors: Steven C. Quay, Henry R. Costantino, Mary S. Kleppe, Ching-Yuan Li
  • NUCLEIC ACID COMPOUNDS FOR INHIBITING ERBB FAMILY GENE EXPRESSION AND USES THEREOF
    Publication number: 20100112687
    Abstract: The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing one or more ERBB family gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to one or more ERBB family mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine and optionally other modifications or combinations thereof. Also provided are methods of decreasing expression of one or more ERBB family gene in a cell or in a subject to treat one or more ERBB family-related disease.
    Type: Application
    Filed: February 28, 2008
    Publication date: May 6, 2010
    Applicant: MDRNA, INC.
    Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
  • NUCLEIC ACID COMPOUNDS FOR INHIBITING GENE EXPRESSION AND USES THEREOF
    Publication number: 20100105134
    Abstract: The present disclosure provides RNA molecules, for example, meroduplex ribonucleic acid molecules (mdRNA), and blunt ended double-stranded ribonucleic acid molecules capable of decreasing or silencing expression of a target gene. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a target mRNA. Also provided are methods of decreasing expression of a target gene in a cell or in a subject to treat a disease or condition associated with the target gene.
    Type: Application
    Filed: September 1, 2009
    Publication date: April 29, 2010
    Applicant: MDRNA, Inc.
    Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
  • NUCLEIC ACID COMPOUNDS FOR INHIBITING WNT GENE EXPRESSION AND USES THEREOF
    Publication number: 20100055784
    Abstract: The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing WNT1, WNT2, or WNT3A gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a WNT1, WNT2, or WNT3A mRNA. In addition, the meroduplex may have at least one uridine is a 5-methyluridine, a nucleoside is a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a WNT1, WNT2, or WNT3A gene in a cell or in a subject to treat a WNT1, WNT2, or WNT3A-related disease.
    Type: Application
    Filed: March 3, 2008
    Publication date: March 4, 2010
    Applicant: MDRNA, INC.
    Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
  • NUCLEIC ACID COMPOUNDS FOR INHIBITING RAS GENE EXPRESSION AND USES THEREOF
    Publication number: 20100055783
    Abstract: The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing RAS (e.g., HRAS, KRAS, NRAS) gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to an HRAS, KRAS, or NRAS mRNA. In addition, the meroduplex may have at least one uridine is a 5-methyluridine, a nucleoside is a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a RAS gene in a cell or in a subject to treat a RAS-related disease.
    Type: Application
    Filed: March 3, 2008
    Publication date: March 4, 2010
    Applicant: MDRNA, INC.
    Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
  • NUCLEIC ACID COMPOUNDS FOR INHIBITING MYC GENE EXPRESSION AND USES THEREOF
    Publication number: 20100055782
    Abstract: The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing MYC gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-over-lapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a MYC mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a MYC gene in a cell or in a subject to treat a MYC-related disease.
    Type: Application
    Filed: March 3, 2008
    Publication date: March 4, 2010
    Applicant: MDRNA, INC.
    Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
  • NUCLEIC ACID COMPOUNDS FOR INHIBITING VEGF FAMILY GENE EXPRESSION AND USES THEREOF
    Publication number: 20100047909
    Abstract: The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing one or more VEGF family gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to one or more VEGF family mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine and optionally other modifications or combinations thereof. Also provided are methods of decreasing expression of one or more VEGF family gene in a cell or in a subject to treat one or more VEGF family-related disease.
    Type: Application
    Filed: February 28, 2008
    Publication date: February 25, 2010
    Applicant: MDRNA, INC.
    Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
  • NUCLEIC ACID COMPOUNDS FOR INHIBITING BCL2 GENE EXPRESSION AND USES THEREOF
    Publication number: 20100041140
    Abstract: The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing BCL2 gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-over-lapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a BCL2 mRNA. In addition, the meroduplex may have at least one uridine is a 5-methyluridine, a nucleoside is a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a BCL2 gene in a cell or in a subject to treat a BCL2-related disease.
    Type: Application
    Filed: February 29, 2008
    Publication date: February 18, 2010
    Applicant: MDRNA, INC.
    Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
  • RIBONUCLEIC ACIDS WITH NON-STANDARD BASES AND USES THEREOF
    Publication number: 20100015708
    Abstract: The present disclosure provides a ribonucleic acid comprising a double-stranded region having at least one base pair comprising a 5-methyluridine base paired with a 2,6-diaminopurine and methods for preparing the same. Also provided are methods for treating or preventing a disease or disorder by inducing RNAi.
    Type: Application
    Filed: June 18, 2009
    Publication date: January 21, 2010
    Applicant: MDRNA, INC.
    Inventors: Steven C. Quay, Narendra K. Vaish
  • NUCLEIC ACID COMPOUNDS FOR INHIBITING HIF1A GENE EXPRESSION AND USES THEREOF
    Publication number: 20100015706
    Abstract: The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing HIF1A gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a HIF1A mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside is a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a HIF1A gene in a cell or in a subject to treat a HIF1A-related disease.
    Type: Application
    Filed: February 28, 2008
    Publication date: January 21, 2010
    Applicant: MDRNA, INC.
    Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
  • PRODUCTION AND USE OF DERIVATIZED HOMOSERINE LACTONES
    Publication number: 20100016424
    Abstract: The present invention provides analogues of autoinducer molecules that are derivatized to allow their attachment to other molecules and surfaces. Libraries of the autoinducer analogues are also contemplated. Also provided are methods for using the compounds of the invention to produce compositions, such as immunoconjugates, antibodies and vaccines, which are useful for treating and preventing disease states in a subject. The compositions of the invention are also useful in various assays, including assessing the autoinducer load in a subject.
    Type: Application
    Filed: July 13, 2009
    Publication date: January 21, 2010
    Applicant: Ensisheim Partners LLC
    Inventor: Steven C. Quay
  • TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS
    Publication number: 20090220435
    Abstract: Compounds and components including sequences for mucosal epithelial transport of an active agent are given. Tight junction modulating peptide components are described for use in transport and delivery. Permeability can be enhanced with reversibility. Compounds and components for enhanced delivery may be peptide or protein variants, conjugates, or other analog types and structures.
    Type: Application
    Filed: July 27, 2006
    Publication date: September 3, 2009
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventors: Steven C. Quay, Shu-Chih Chen Quay, Kunyuan Cui, Anthony P. Sileno, Paul Hickok Johnson, Michael E. Houston, Henry R. Costantino, Michael V. Templin
  • Production and use of derivatized homoserine lactones
    Patent number: 7560572
    Abstract: The present invention provides analogues of autoinducer molecules that are derivatized to allow their attachment to other molecules and surfaces. Libraries of the autoinducer analogues are also contemplated. Also provided are methods for using the compounds of the invention to produce compositions, such as immunoconjugates, antibodies and vaccines, which are useful for treating and preventing disease states in a subject. The compositions of the invention are also useful in various assays, including assessing the autoinducer load in a subject.
    Type: Grant
    Filed: January 13, 2004
    Date of Patent: July 14, 2009
    Assignee: K-Quay Enterprises, LLC
    Inventor: Steven C. Quay
  • COMPOSITIONS FOR ENHANCED EPITHELIAL PERMEATION OF PEPTIDE YY FOR TREATING OBESITY
    Publication number: 20090118158
    Abstract: Pharmaceutical compositions comprising PYY(3-36), a cyclodextrin, and a compound selected from phosphatidylcholine or diglyceride, wherein the PYY(3-36) is present in an amount effective to alleviate one or more symptom(s) of obesity in a subject, and the cyclodextrin and the compound selected from phosphatidylcholine or diglyceride are present in an amount sufficient to enhance epithelial permeation.
    Type: Application
    Filed: September 19, 2008
    Publication date: May 7, 2009
    Applicant: NASTECH PHARMACEUTICAL COMPANY INC.
    Inventor: Steven C. Quay